SA
Sign upLog In
NICXF

Nicox S.A. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. The company's lead product candidate, NCX 470, is designed to treat glaucoma and ocular hypertension, leveraging its proprietary nitric oxide-donating technology to enhance intraocular pressure reduction. Nicox operates primarily in Europe and the U.S., positioning itself in a competitive market with significant unmet medical needs.

HealthcareBiotechnologymoderate - The company has low fixed costs due to its clinical-stage status, but as it moves towards commercialization, it may experience increased fixed costs related to manufacturing and marketing.

Business Overview

01Product sales from NCX 470 - 100%

Nicox generates revenue through the development and potential commercialization of its ophthalmic products, particularly NCX 470. The company benefits from a unique competitive advantage through its proprietary technology that enhances the efficacy of existing treatments, allowing for premium pricing. Partnerships with larger pharmaceutical companies could also provide milestone payments and royalties.

What Moves the Stock

Clinical trial results for NCX 470, particularly Phase 3 outcomes

Regulatory approvals from the FDA or EMA

Partnership announcements with larger pharmaceutical companies

Market adoption rates post-launch

Watch on Earnings
Clinical trial milestonesRegulatory approval timelinesMarket share projections post-commercialization

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption in ophthalmic treatments

Emergence of alternative therapies for glaucoma

Increased competition from established pharmaceutical companies

Limited cash reserves impacting operational flexibility

Potential dilution from future capital raises

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The demand for ophthalmic treatments is relatively inelastic, less affected by economic cycles.

Interest Rates

Minimal impact as Nicox is not heavily reliant on debt financing, but higher rates could affect overall market sentiment towards biotech investments.

Credit

minimal

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors are likely attracted to the potential for rapid revenue growth upon successful product commercialization.

high - The stock is likely to exhibit high volatility due to binary outcomes associated with clinical trials and regulatory approvals.

Key Metrics to Watch
Clinical trial enrollment rates
FDA approval timelines for NCX 470
Market penetration rates post-launch
Partnership developments

Explore More

NICXF Financial Metrics

Explore 130+ historical metrics & ratios

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

S&P 500 Sector Leaderboards

All SectorsTechnologyHealthcareFinancial ServicesConsumer CyclicalCommunication ServicesIndustrialsConsumer DefensiveEnergyUtilitiesReal EstateBasic Materials

Fundamental Metric Rankings

P/E RatioReturn on Equity (ROE)ROICGross MarginOperating MarginNet Profit MarginRevenue GrowthEPS GrowthNet Income GrowthPrice to Sales (P/S)Price to Book (P/B)Price to Free Cash FlowDebt to EquityCurrent RatioQuick RatioCash Ratio
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.